LncRNA BLACAT1 Promotes Proliferation, Migration and Invasion of Prostate Cancer Cells Via Regulating MiR-29a-3p/DVL3 Axis

Overview

Journal Technol Cancer Res Treat

Specialties Biomedical Engineering
Oncology
Pharmacology

Date 2021 Mar 1

PMID 33641528

Citations 7

Authors

Bo Liao

Shuangquan Chen

Yugen Li

Zhaohui Yang

Ying Yang

Xianzhong Deng

Sha Ke

Affiliations

Soon will be listed here.

Abstract

Background: Long non-coding RNA bladder cancer associated transcript 1 (BLACAT1) is oncogenic in several types of cancers. However, little is known concerning its expression and function in prostate cancer.

Methods: Paired prostate cancer samples were collected, and the expression levels of BLACAT1, miR-29a-3p and disheveled segment polarity protein 3 (DVL3) were examined by quantitative real-time polymerase chain reaction (qRT-PCR); BLACAT1 shRNAs were transfected into PC-3 and LNCaP cell lines, and proliferative ability was detected by cell counting kit-8 (CCK-8) assay; qRT-PCR and Western blot were used to analyze the changes of miR-29a-3p and DVL3; dual-luciferase reporter gene assay was used to determine the regulatory relationships between miR-29a-3p and BLACAT1, and miR-29a-3p and DVL3.

Results: BLACAT1 expression was significantly up-regulated in cancerous tissues of prostate cancer samples and positively correlated with the expression of DVL3, while negatively associated with miR-29a-3p. After the transfection of BLACAT1 shRNAs into prostate cancer cells, the proliferative ability and metastatic ability of cancer cells were significantly inhibited; BLACAT1 shRNAs could reduce the expression of DVL3 on both mRNA and protein expressions levels, the luciferase activity of BLACAT1 reporter was inhibited by miR-29a-3p, and DVL3 was validated as a target gene of miR-29a-3p.

Conclusion: BLACAT1 expression is abnormally up-regulated in prostate cancer tissues. BLACAT1 can modulate the proliferative and metastatic ability of prostate cancer cells and have the potential to be the "ceRNA" to regulate the expression of DVL3 by sponging miR-29a-3p.

Citing Articles

Current landscape of exosomal non-coding RNAs in prostate cancer: Modulators and biomarkers.

Li Y, Tang X, Wang B, Chen M, Zheng J, Chang K Noncoding RNA Res. 2024; 9(4):1351-1362.

PMID: 39247145 PMC: 11380467. DOI: 10.1016/j.ncrna.2024.07.003.

CENPA knockdown restrains cell progression and tumor growth in breast cancer by reducing PLA2R1 promoter methylation and modulating PLA2R1/HHEX axis.

Wu G, Fan Z, Li X Cell Mol Life Sci. 2024; 81(1):27.

PMID: 38212546 PMC: 11072086. DOI: 10.1007/s00018-023-05063-5.

Identification of a potential competing endogenous RNA (ceRNA) network in gastric adenocarcinoma.

Wu C, Hou X, Li S, Wang J, Luo S J Gastrointest Oncol. 2023; 14(2):1019-1036.

PMID: 37201096 PMC: 10186539. DOI: 10.21037/jgo-22-1201.

Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer.

Taheri M, Badrlou E, Hussen B, Kashi A, Ghafouri-Fard S, Baniahmad A Front Oncol. 2023; 13:1123101.

PMID: 37025585 PMC: 10070735. DOI: 10.3389/fonc.2023.1123101.

The interplay between non-coding RNAs and Wnt/ß-catenin signaling pathway in urinary tract cancers: from tumorigenesis to metastasis.

Rahmani F, Safavi P, Fathollahpour A, Sabz F, Tajzadeh P, Arefnezhad M EXCLI J. 2022; 21:1273-1284.

PMID: 36483915 PMC: 9727268. DOI: 10.17179/excli2022-5348.

References

Hua J, Ahmed M, Guo H, Zhang Y, Chen S, Soares F . Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. Cell. 2018; 174(3):564-575.e18. DOI: 10.1016/j.cell.2018.06.014. View

Lu H, Liu H, Yang X, Ye T, Lv P, Wu X . LncRNA BLACAT1 May Serve as a Prognostic Predictor in Cancer: Evidence from a Meta-Analysis. Biomed Res Int. 2019; 2019:1275491. PMC: 6466934. DOI: 10.1155/2019/1275491. View

Pai V, Hsu C, Chan T, Liao W, Chuu C, Chen W . ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-β-catenin signaling. Oncogene. 2018; 38(8):1340-1353. DOI: 10.1038/s41388-018-0497-4. View

Zheng P, Li H, Xu P, Wang X, Shi Z, Han Q . High lncRNA HULC expression is associated with poor prognosis and promotes tumor progression by regulating epithelial-mesenchymal transition in prostate cancer. Arch Med Sci. 2018; 14(3):679-686. PMC: 5949918. DOI: 10.5114/aoms.2017.69147. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Sekhon K, Bucay N, Majid S, Dahiya R, Saini S . MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget. 2016; 7(41):67597-67611. PMC: 5341899. DOI: 10.18632/oncotarget.11708. View

Zhao Z, Wang L, Song W, Cui H, Chen G, Qiao F . Reduced miR-29a-3p expression is linked to the cell proliferation and cell migration in gastric cancer. World J Surg Oncol. 2015; 13:101. PMC: 4363339. DOI: 10.1186/s12957-015-0513-x. View

Meng F, Meng F, Wu H, Cao X . miR-564 inhibited metastasis and proliferation of prostate cancer by targeting MLLT3. Eur Rev Med Pharmacol Sci. 2017; 21(21):4828-4834. View

Acunzo M, Romano G, Wernicke D, Croce C . MicroRNA and cancer--a brief overview. Adv Biol Regul. 2014; 57:1-9. DOI: 10.1016/j.jbior.2014.09.013. View

10.

Le L, Swingler T, Crowe N, Vincent T, Barter M, Donell S . The microRNA-29 family in cartilage homeostasis and osteoarthritis. J Mol Med (Berl). 2015; 94(5):583-96. PMC: 4856728. DOI: 10.1007/s00109-015-1374-z. View

11.

Yang G, Lu X, Yuan L . LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014; 1839(11):1097-109. DOI: 10.1016/j.bbagrm.2014.08.012. View

12.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

13.

He H, Wang N, Yi X, Tang C, Wang D . Long non-coding RNA H19 regulates E2F1 expression by competitively sponging endogenous miR-29a-3p in clear cell renal cell carcinoma. Cell Biosci. 2017; 7:65. PMC: 5709834. DOI: 10.1186/s13578-017-0193-z. View

14.

Lei H, Gao Y, Xu X . LncRNA TUG1 influences papillary thyroid cancer cell proliferation, migration and EMT formation through targeting miR-145. Acta Biochim Biophys Sin (Shanghai). 2017; 49(7):588-597. DOI: 10.1093/abbs/gmx047. View

15.

Wang C, Li Y, Tian H, Bao X, Wang Z . Long non-coding RNA BLACAT1 promotes cell proliferation, migration and invasion in cervical cancer through activation of Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018; 22(10):3002-3009. DOI: 10.26355/eurrev_201805_15057. View

16.

Huang S, Wa Q, Pan J, Peng X, Ren D, Huang Y . Downregulation of miR-141-3p promotes bone metastasis via activating NF-κB signaling in prostate cancer. J Exp Clin Cancer Res. 2017; 36(1):173. PMC: 5716366. DOI: 10.1186/s13046-017-0645-7. View

17.

Dong Z, Wang Y . LncRNA BLACAT1 accelerates the proliferation and migration of osteosarcoma cells through regulating STAT3. Pathol Res Pract. 2019; 215(3):571-579. DOI: 10.1016/j.prp.2019.01.017. View

18.

Zou Y, Xie C, Yang S, Xiong J . AMPK activators suppress breast cancer cell growth by inhibiting DVL3-facilitated Wnt/β-catenin signaling pathway activity. Mol Med Rep. 2016; 15(2):899-907. DOI: 10.3892/mmr.2016.6094. View

19.

Wang X, Liu S, Cao L, Zhang T, Yue D, Wang L . miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma. Oncotarget. 2017; 8(49):86592-86603. PMC: 5689709. DOI: 10.18632/oncotarget.21246. View

20.

Vishnoi A, Rani S . MiRNA Biogenesis and Regulation of Diseases: An Overview. Methods Mol Biol. 2016; 1509:1-10. DOI: 10.1007/978-1-4939-6524-3_1. View